A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy
A study for patients with previously untreated Multiple Myeloma
Sponsor: Johnson & Johnson
Enrolling: Male and Female Patients
IRB Number: AAAP6420
U.S. Govt. ID: NCT02252172
Contact: Ryan Shelton: 212-304-5485 / rs3323@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out how well Daratumumab works when it is given along with two other drugs called Lenalidomide and Dexamethasone compared to the drug combination of Lenalidomide and Dexamethasone to treat multiple myeloma.
This study is closed
Divaya Bhutani, MD
Do You Qualify?
Do you have multiple myeloma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Ryan Shelton